Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
See This Special Report to Get the Full Story
Jason Rickard net worth and biography

Jason Rickard Biography and Net Worth

Mr. Rickard joined Ironwood in 2012. Mr. Rickard has served as our chief operating officer since April 2020. Prior to his appointment as the company’s senior vice president, chief operating officer, Mr. Rickard had been the company’s senior vice president, operations since July 2018, in which Mr. Rickard most recently led the company’s manufacturing, pharmaceutical development, quality, human resources, information technology and facilities functions. Before becoming senior vice president, operations, Mr. Rickard served as the company’s vice president global operations and information technology from July 2015 to July 2018; vice president global operations from March 2014 to July 2015; vice president commercial manufacturing supply chain from June 2013 to March 2014; and head of supply chain from January 2012 to June 2013. Prior to joining Ironwood, Mr. Rickard was with Genentech, Inc. from 2000 to 2012 in roles of increasing responsibility in manufacturing and supply chain. Mr. Rickard began his career as a mechanical engineer at AMOT Controls Corporation. Mr. Rickard holds an M.S. from California State University—Sacramento and a B.S. from California State University—Chico, both in mechanical engineering.

What is Jason Rickard's net worth?

The estimated net worth of Jason Rickard is at least $4.56 million as of August 9th, 2022. Mr. Rickard owns 376,730 shares of Ironwood Pharmaceuticals stock worth more than $4,562,200 as of December 1st. This net worth evaluation does not reflect any other assets that Mr. Rickard may own. Additionally, Mr. Rickard receives an annual salary of $959,330.00 as COO at Ironwood Pharmaceuticals. Learn More about Jason Rickard's net worth.

How old is Jason Rickard?

Mr. Rickard is currently 51 years old. There are 6 older executives and no younger executives at Ironwood Pharmaceuticals. The oldest executive at Ironwood Pharmaceuticals is Mr. Thomas A. McCourt, CEO & Director, who is 65 years old. Learn More on Jason Rickard's age.

What is Jason Rickard's salary?

As the COO of Ironwood Pharmaceuticals, Inc., Mr. Rickard earned a total compensation package of $3,479,230.00 in 2021. Mr. Rickard earned a salary of $492,589.00, a bonus of $121,050.00, stock awards of $2,519,901.00, non-equity compensation of $327,600.00, and other compensation of $18,090.00.The highest earning executive at Ironwood Pharmaceuticals is Mr. Thomas A. McCourt, CEO & Director, who commands a salary of $1,570,000.00 per year. Learn More on Jason Rickard's salary.

How do I contact Jason Rickard?

The corporate mailing address for Mr. Rickard and other Ironwood Pharmaceuticals executives is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. Ironwood Pharmaceuticals can also be reached via phone at (617) 621-7722 and via email at [email protected] Learn More on Jason Rickard's contact information.

Has Jason Rickard been buying or selling shares of Ironwood Pharmaceuticals?

Jason Rickard has not been actively trading shares of Ironwood Pharmaceuticals within the last three months. Most recently, Jason Rickard sold 18,041 shares of the business's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $11.75, for a transaction totalling $211,981.75. Following the completion of the sale, the chief operating officer now directly owns 376,730 shares of the company's stock, valued at $4,426,577.50. Learn More on Jason Rickard's trading history.

Who are Ironwood Pharmaceuticals' active insiders?

Ironwood Pharmaceuticals' insider roster includes Mark Currie (Director), Alexander Denner (Director), Thomas McCourt (CEO), Julie McHugh (Director), Jason Rickard (COO), Michael Shetzline (CMO), and Ronald Silver (Insider). Learn More on Ironwood Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Ironwood Pharmaceuticals?

During the last twelve months, insiders at the biotechnology company sold shares 12 times. They sold a total of 470,787 shares worth more than $5,502,789.36. The most recent insider tranaction occured on October, 3rd when CEO Thomas A Mccourt sold 18,899 shares worth more than $196,738.59. Insiders at Ironwood Pharmaceuticals own 13.1 % of the company. Learn More about insider trades at Ironwood Pharmaceuticals.

Information on this page was last updated on 10/3/2022.

Jason Rickard Insider Trading History at Ironwood Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/9/2022Sell18,041$11.75$211,981.75376,730View SEC Filing Icon  
12/16/2021Sell27,000$11.28$304,560.00View SEC Filing Icon  
11/23/2021Sell17,193$11.58$199,094.94View SEC Filing Icon  
5/24/2021Sell516$12.25$6,321.00362,538View SEC Filing Icon  
See Full Table

Jason Rickard Buying and Selling Activity at Ironwood Pharmaceuticals

This chart shows Jason Rickard's buying and selling at Ironwood Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ironwood Pharmaceuticals Company Overview

Ironwood Pharmaceuticals logo
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $11.94
Low: $11.89
High: $12.11

50 Day Range

MA: $10.88
Low: $9.90
High: $12.11

2 Week Range

Now: $11.94
Low: $9.73
High: $12.95

Volume

42,737 shs

Average Volume

1,768,811 shs

Market Capitalization

$1.83 billion

P/E Ratio

12.57

Dividend Yield

N/A

Beta

0.99
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
See This Special Report to Get the Full Story